Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson Steps Up Medical Device Investment In China

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson, known in China for its personal care and infant products, has of late stepped up efforts in its medical device business. Now the firm's second largest portfolio-with sales overtaking drugs and consumables for the past five consecutive years-medical device sales and profit have surpassed 36 percent growth annually. The firm also plans to acquire local companies in the sector to rapidly penetrate into the medium- and low-end medical device business, widely regarded as the first segment to benefit from China's health care reform. Johnson & Johnson is in the process of buying domestic firm DaBao Daily Chemicals; if successful, the 2.3 billion yuan deal will be J&J's biggest acquisition in China. (Click here for more - Chinese language)

You may also be interested in...

J&J Opens Device Plant In Suzhou, Expects Larger Piece Of China’s Growing Device Market

BEIJING - Johnson & Johnson's medical device manufacturing base started operation in China's southern city of Suzhou, the company announced April 22

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts